Content
@
0 reply
0 recast
0 reaction
christin
@christin
I've helped dozens of pharmaceutical companies educate healthcare providers about diseases, the latest treatment options, and the harrowing journey patients go through. You would think these are topics that medical schools cover, but healthcare is evolving so quickly that continual medical education is often provided by drug companies. Education is especially vital for rare diseases. They are not top-of-mind for healthcare professionals because they're by definition uncommon. I remember working on marketing a drug for idiopathic pulmonary fibrosis, a rare lung disease. Since treatments available only slowed down progression and are not curative, doctors often opted to "watch and wait." This robbed patients of years of their lives in a silent way. Both my company and the competitor spent millions on medical education, bc the true competitor wasn't between the companies, it was against the inertia of "watch and wait." Yet inertia can be conquered: by educating customers, we empowered them to take action.
17 replies
8 recasts
94 reactions
[email protected]
@ilyavad6
What you said about rare diseases being especially important to educate on is so valid fr.nn I can really relate to frustration and sadness that comes with watching patients suffer from a condition that's not well understood or treated.nnAnd icl idiopathic pulmonary fibrosis drug you worked on is a GREAT feat, christin. nnWhat inspired you to pursue a career in pharmaceutical education, and what do you think is the most important aspect of this work
0 reply
0 recast
0 reaction
